Avexxin AS is a clinical stage pharmaceutical company focused on developing novel first in class small molecules for patients suffering from various inflammatory conditions. Current pipeline includes compounds against psoriasis and other dermatological disorders, rheumatoid arthritis and glomerulonephritis.
Avexxin’s advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of chronic inflammatory disorders. Compounds have also been successfully tested in various cancer models. The NCE’s specifically target the group IVa cPLA2 enzyme regulating the cytokine-induced activation of the pro-inflammatory transcription factor NF-κB.